English | 简体中文 | LP ACCESS

About artrix

This author has not yet filled in any details.
So far artrix has created 72 blog entries.

ScienTech Medical Technology, a Vivo Capital portfolio company, Successfully Lists on the Main Board of Hong Kong Stock Exchange

ScienTech Medical Technology, a Vivo Capital portfolio company, Successfully Lists on the Main Board of Hong Kong Stock Exchange2022-11-09T23:02:31-08:00

Vivo Capital Invests in Zenas Biopharma’s $118 Million Financing to Advance the Company’s Broad Pipeline of Autoimmune Disease Therapeutics

Vivo Capital Invests in Zenas Biopharma’s $118 Million Financing to Advance the Company’s Broad Pipeline of Autoimmune Disease Therapeutics2022-11-09T22:59:01-08:00

NMPA Approves Suzhou Omni’s Compound Ipratropium Bromide Solution for Inhalation to Treat Symptoms of COPD and Asthma

NMPA Approves Suzhou Omni’s Compound Ipratropium Bromide Solution for Inhalation to Treat Symptoms of COPD and Asthma2022-09-30T02:06:18-07:00

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older2022-08-03T22:23:46-07:00

Avistone Pharmaceuticals Secures $200M Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital

Avistone Pharmaceuticals Secures $200M Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital2022-03-09T22:05:12-08:00

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 2022-03-09T21:58:39-08:00

Palo Alto
Global Headquarters

Beijing
 

Shanghai 
 

Taipei  
 

Hong Kong   
 

Email: info@vivocapital.com
Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved.
Go to Top